A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)

Tryfonidis K., Basaran G., Bogaerts J., Debled M., Dirix L., Thery J., ...Daha Fazla

EUROPEAN JOURNAL OF CANCER, cilt.53, ss.144-154, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 53
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1016/j.ejca.2015.10.012
  • Dergi Adı: EUROPEAN JOURNAL OF CANCER
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.144-154
  • Anahtar Kelimeler: Anastrozole, Gefitinib, Metastatic breast cancer, Endocrine resistance, FIRST-LINE THERAPY, POSTMENOPAUSAL WOMEN, RESISTANCE, TAMOXIFEN, PALBOCICLIB, FULVESTRANT, MANAGEMENT, SUPERIOR, PATHWAY, IRESSA
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

Background: Preclinical data suggest that epidermal growth factor receptor (EGFR) inhibitors (e.g. gefitinib) can delay endocrine resistance in breast cancer. A double-blind, placebo-controlled, phase II trial investigated whether adding gefitinib (G) to anastrozole (A) would improve outcome in advanced breast cancer (ABC).